The impact of biosimilars ’ entry in the EU market
This document has been prepared in the framework of a service contract with the European Commission (Directorate-General for Enterprise and Industry). The views expressed therein are purely those of the writers and should not be regarded as stating a position of the European Commission or its servic...
| Main Authors: | , , , |
|---|---|
| Other Authors: | |
| Format: | Text |
| Language: | English |
| Published: |
2011
|
| Subjects: | |
| Online Access: | http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.357.2218 http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/biosimilars_market_012011_en.pdf |
| Summary: | This document has been prepared in the framework of a service contract with the European Commission (Directorate-General for Enterprise and Industry). The views expressed therein are purely those of the writers and should not be regarded as stating a position of the European Commission or its services. The European Commission does not guarantee the accuracy of the data included in this document, nor does it accept responsibility for the use made thereof. Acknowledgements The authors thank IMS Spain for kindly providing us with the analysis of market data from the MIDAS database. Data have been collected from the database and elaborated by Leandro Lindner and Emmanuel Jiménez. We would like also to thank Sabine Vogler (GÖG/ÖBIG), Sotiris Vandoros (LSE), Suzette Kox and Paul Greenland (EGA) and Christophe Roeland, Thomas Heynish and Hilda Juhasz (EC) for their comments and inputs. Finally, despite all the above contributions, the authors remain responsible for |
|---|